At last. After being the first new agent to gain approval for weight control in the US in more than a decade, Arena Pharmaceutical’s novel antiobesity agent Belviq (lorcaserin) was launched on June 7 and is available in pharmacies from June 11. Read more.
Presentations regarding the use of Avastin in glioblastoma (GBM) were prominent in the Central Nervous System Cancer and Plenary Session during this years’ ASCO annual meeting, with the focus being the newly diagnosed GBM treatment setting. Read more.
The undeniable success story of ASCO 2012 was Bristol Myers-Squibb’s anti-programmed death-1 (PD-1) antibody, nivolumab (BMS-936558). Phase Ib data suggested nivolumab use was associated with rapid and durable responses in heavily pre-treated patients across multiple tumor types; namely malignant melanoma, renal cell carcinoma and non-small cell lung cancer. Read more.
The Centers for Medicare & Medicaid Services made a decision last week that could cut into the profits of Part D plans and certainly focuses more attention on how they are spending premium revenue. Read more.
Joseph Dwyer and Conor Walsh
On May 24, the European Commission approved Bayer’s novel oral anticoagulant rivaroxaban (Xarelto) for the secondary prevention of atherothrombotic events (cardiovascular death, myocardial infarction or stroke) after an acute coronary syndrome (ACS) in adult patients with elevated cardiac biomarkers. Read more.
Selected Themes at EASL 2013
Contributor: Efua Edusei Read more.
Decision Resources’ Pharmaview team will be present at the annual American Society of Clinical Oncology (ASCO) conference in Chicago, from the 31st of May through the 4th of June 2013. We shall provide our insights and analysis on the major breakthrough therapies, updates in treatment algorithms, and novel pathways of interest in the treatment of cancer. Below is a summary of key abstracts and data which we expect will be highlights at this year's conference.
I have just returned from the Heart Rhythm Society meeting in Denver, CO. The meeting was heavily focused on surgical and device implantation procedures, and particularly around anticoagulation in the peri-procedural setting. Two of the studies presented during the first late-breaking clinical trials session were focused on this issue. Read more.
If recent regulatory decisions in the obesity space have given a renewed sense of optimism in the United States, the opposite is true in Europe.
Rarely a day goes by without mention in the media of obesity and its comorbidities, including type 2 diabetes mellitus and hypertension. There are constant reports on the significant impact of the obesity epidemic on patients, healthcare resources, and society. Patients, physicians, and politicians have long been highlighting the need for safe, effective, and simple treatments. Read more.